Winch Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Winch Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$712	–	532
2024 Q4	$712	Buy	+1	New	+$839	﹤0.01%	492
2015 Q3	–	Sell	-144	Closed	-$73K	–	270
2015 Q2	$73K	Buy	+144	New	+$70.3K	0.04%	101

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Winch Advisory Services's REGN Position: Q1 2025 in Review

Winch Advisory Services sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1 share — an estimated $712 sold.

Winch Advisory Services first reported a position in REGN in Q2 2015 and held it in 2 quarters. The position peaked at $73K in Q2 2015. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Winch Advisory Services reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Winch Advisory Services sold 1 Regeneron Pharmaceuticals share in Q1 2025, an estimated $712.
Winch Advisory Services first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 2 quarters.
Winch Advisory Services's Regeneron Pharmaceuticals position peaked at $73K in Q2 2015.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Winch Advisory Services's 13F filing for Q1 2025, filed 6 May 2025.